Description
2-Amino-6-methyl-3-nitropyridine (CAS No. 21901-29-1) is a high-purity nitropyridine derivative widely utilized in pharmaceutical, agrochemical, and material science research. This compound, with the molecular formula C6H7N3O2, serves as a critical intermediate in the synthesis of heterocyclic compounds, active pharmaceutical ingredients (APIs), and specialty chemicals. Its unique structural features, including the amino and nitro functional groups, make it a versatile building block for nucleophilic substitution and coupling reactions.
Our product is rigorously tested for quality, ensuring ≥97% purity (HPLC) with minimal impurities. Supplied as a fine yellow crystalline powder, it is packaged under inert conditions to guarantee stability and longevity. Ideal for laboratory-scale and industrial applications, this compound is compatible with standard organic solvents such as DMSO, ethanol, and dichloromethane.
Applications span from drug discovery (e.g., kinase inhibitors) to coordination chemistry. Available in quantities from grams to kilograms, each batch includes detailed analytical documentation (COA, MSDS, NMR/HPLC spectra). Store in a cool, dry place (2-8°C) under nitrogen for optimal shelf life.
Properties
- CAS Number: 21901-29-1
- Complexity: 156
- IUPAC Name: 6-methyl-3-nitro-pyridin-2-amine
- InChI: InChI=1S/C6H7N3O2/c1-4-2-3-5(9(10)11)6(7)8-4/h2-3H,1H3,(H2,7,8)
- InChI Key: LCJXSRQGDONHRK-UHFFFAOYSA-N
- Exact Mass: 153.053826475
- Molecular Formula: C6H7N3O2
- Molecular Weight: 153.14
- SMILES: CC1=NC(=C(C=C1)[N+](=O)[O-])N
- Topological: 84.7
- Monoisotopic Mass: 153.053826475
- Synonyms: 2-Amino-6-methyl-3-nitropyridine, 691-453-9, 21901-29-1, 2-Amino-3-nitro-6-picoline, 6-methyl-3-nitropyridin-2-amine, 2-amino-3-nitro-6-methylpyridine, 6-Amino-5-nitro-2-picoline, 6-methyl-3-nitro-pyridin-2-ylamine, MFCD00047443, 6-Methyl-3-nitro-2-pyridinamine, 2-PYRIDINAMINE, 6-METHYL-3-NITRO-, 2-amino-3-nitro-6-methyl pyridine, NSC16024, SCHEMBL801582, SCHEMBL28246491, 6-methyl-3-nitro-2-pyridylamine, DTXSID10280230, 2-amino-3-nitro-6-methyl-pyridine, 2-amino-6-methyl-3-nitro-pyridine, 6-Amino-5-nitro-2-picoline; 2-Amino-6-methyl-3-nitropyridine, ALBB-032236, BCP22134, CS-D0765, GEO-00190, NSC-16024, SBB004045, AKOS002676260, AB02051, DS-0471, PS-4872, 2-Amino-6-methyl-3-nitropyridine, 97%, AC-25164, SY021198, DB-027731, A2334, EN300-98487, AJ-333/25006082, Z1203162410, 2-Amino-3-nitro-6-picoline (2-Amino-6-methyl-3-nitropyridine), 2-Amino-6-methyl-3-nitropyridine;6-methyl-3-nitropyridin-2-amine
2-Amino-6-methyl-3-nitropyridine is primarily employed as a key intermediate in the synthesis of complex heterocycles for drug development, particularly in anticancer and antimicrobial research. Its reactive nitro group facilitates palladium-catalyzed cross-coupling reactions, while the amino group enables derivatization via acylation or alkylation. Researchers also utilize it in metal-organic frameworks (MOFs) and as a ligand precursor in catalytic systems. Suitable for small-molecule screening libraries due to its drug-like properties.
Safety and Hazards
GHS Hazard Statements
- H302 (97.5%): Harmful if swallowed [Warning Acute toxicity, oral]
- H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
- H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
- H334 (97.5%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]
Precautionary Statements
- P233, P260, P264, P264+P265, P270, P271, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P321, P330, P332+P317, P337+P317, P342+P316, P362+P364, P403, and P501
Hazard Classes and Categories
- Acute Tox. 4 (97.5%)
- Skin Irrit. 2 (100%)
- Eye Irrit. 2 (100%)
- Resp. Sens. 1 (97.5%)
If you are interested or have any questions, please contact us at support@atomfair.com
Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.


Reviews
There are no reviews yet.